Yep, two nice points called out:
1. ”Dr McKibbon says Botanix doesn’t need the dosh - one-third of which is not drawn downimmediately - for its current Sofdra roll-out in the US.“But if an acquisition opportunity emerges, it does not have to hinge on a capital raising,”he says. “It allows us to be nimble.”
2. “Meanwhile, three months after the US Sofdra launch, prescriptions have exceededmanagement’s expectations.“
Yep, two nice points called out:1. ”Dr McKibbon says Botanix...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 31.0¢ | 29.5¢ | $2.519M | 8.363M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 255404 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 226506 | 5 |
View Market Depth
| Last trade - 16.11pm 23/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |